2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (with Post-Guideline Evidence Landscape Through 2025)
Core US guideline for HF management: four-pillar GDMT for HFrEF, SGLT2 inhibitors across the EF spectrum, and risk-based advanced therapy referral. Read together with post-guideline trials (FINEARTS-HF, STEP-HFpEF, IRONMAN) that have since expanded the evidence base for HFpEF/HFmrEF.
What changed in this edition
- Quadruple GDMT for HFrEF: ARNI (preferred) or ACEi/ARB, beta-blocker, MRA, and SGLT2 inhibitor; parallel initiation favored.
- SGLT2 inhibitors recommended across the EF spectrum (Class 2a for HFmrEF/HFpEF in the 2022 guideline; reinforced by EMPEROR-Preserved and DELIVER).
- Post-2022 evidence: FINEARTS-HF supports finerenone in HFmrEF/HFpEF; STEP-HFpEF supports semaglutide 2.4 mg for HFpEF with obesity; IRONMAN supports IV iron for HFrEF with iron deficiency.
- Advanced HF referral on INTERMACS clues: recurrent admissions, inotrope dependence, worsening renal function, or intolerance of GDMT.
- ICD/CRT per standard criteria after ≥90 days of optimized GDMT.
- Structured transitions of care with early post-discharge follow-up to reduce readmission.
- Cardiac rehabilitation and palliative care integration recommended across the HF trajectory.
Clinical takeaways
The four pillars
ARNI (or ACEi/ARB), beta-blocker, MRA, and SGLT2 inhibitor should be started within the first hospitalization or first two clinic visits. Low doses of all beats high doses of few.
HFpEF is treatable
SGLT2i (Class 2a in 2022 guideline; supported by EMPEROR-Preserved and DELIVER). Post-guideline evidence supports finerenone (FINEARTS-HF, 2024) and semaglutide 2.4 mg for the obesity phenotype (STEP-HFpEF, 2023). Diuretics for congestion. Confirm diagnosis with invasive hemodynamics when ambiguous.
Iron, obesity, and metabolic targets
Check ferritin and TSAT at every HF admission; treat iron deficiency even without anemia. Treat obesity as a disease driver. Optimize T2D and CKD co-therapies.
Device and advanced therapy triggers
ICD/CRT per standard criteria at 90 days of GDMT. Refer for advanced HF evaluation on INTERMACS clues: recurrent admissions, inotrope dependence, worsening renal function, or intolerance of GDMT.
Transitions of care
Early post-discharge visit (within 7 days), formal transition checklist, pharmacist-led titration, and remote weight/BP monitoring reduce readmission.
Supporting trials
- DAPA-HFPubMed 31535829
Dapagliflozin reduced HF events and mortality in HFrEF.
- EMPEROR-PreservedPubMed 34449189
Empagliflozin reduced HF events in HFpEF, extending SGLT2i benefit across the EF spectrum.
- FINEARTS-HFPubMed 39225278
Finerenone reduced worsening HF events in HFmrEF/HFpEF.
- STEP-HFpEFPubMed 37622681
Semaglutide improved symptoms and exercise function in HFpEF with obesity.
- IRONMANPubMed 36347265
IV ferric derisomaltose reduced HF hospitalizations in iron-deficient HFrEF.
Related reading
SGLT2 Inhibitors in Heart Failure: Evidence, Dosing, and Clinical Decision Points
DAPA-HF and EMPEROR-Reduced established SGLT2 inhibitors as foundational HFrEF therapy. DELIVER and EMPEROR-Preserved extended the benefit to HFpEF. Here is the trial-by-trial evidence and practical prescribing guidance for your heart failure patients.
Clinical ReasoningChronic Heart Failure Monitoring: NT-proBNP Guided Therapy
Natriuretic peptide-guided heart failure management remains debated despite multiple randomized trials. This review evaluates NT-proBNP targets, the GUIDE-IT trial limitations, and practical strategies for incorporating biomarker trends into therapeutic decision-making.
Evidence-Based MedicineSGLT2 Inhibitors in HFpEF with CKD: What the Evidence Shows
A 72-year-old with HFpEF, eGFR 34, type 2 diabetes, and a recent heart failure hospitalization. Should she start an SGLT2 inhibitor? The answer spans three trial programs, and the data are clearer than you might expect.